MedPath

Abnormal uterine bleeding

Not Applicable
Conditions
Fertility-female
treatment of endometrial hyperplasia without atypia
Registration Number
PACTR201508001237608
Lead Sponsor
Faculty of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Other
Sex
Female
Target Recruitment
100
Inclusion Criteria

no prior diagnosis of endometrial carcinoma, an intact uterus, with histologically confirmed endometrial hyperplasia (EH) without atypia

Exclusion Criteria

Women with associated pathology as uterine fibroid, cervical or vaginal pathology, bleeding tendency, chronic liver disease and any contraindications to progestin therapy were excluded from the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
regression of hyperplasia after 6 months of progestin therapy.
Secondary Outcome Measures
NameTimeMethod
adverse effects;patient acceptability
© Copyright 2025. All Rights Reserved by MedPath